Arno Therapeutics Inc (ARNI) financial statements (2020 and earlier)
Company profile
| Business Address |
200 ROUTE 31 NORTH FLEMINGTON, NJ 08822 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 9/30/2016 TTM | 12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | |||
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Current Assets | |||||||
| Cash, cash equivalents, and short-term investments | 0 | 8 | 27 | 11 | |||
| Cash and cash equivalents | 0 | 8 | 27 | 11 | |||
| Prepaid expense and other current assets | ✕ | ✕ | ✕ | ✕ | 0 | ||
| Other undisclosed current assets | 0 | 0 | 0 | ||||
| Total current assets: | 0 | 8 | 27 | 11 | |||
| Noncurrent Assets | |||||||
| Property, plant and equipment | 0 | 0 | 0 | 0 | |||
| Deposits noncurrent assets | 0 | 0 | 0 | 0 | |||
| Deferred costs | 2 | ||||||
| Total noncurrent assets: | 0 | 0 | 0 | 2 | |||
| TOTAL ASSETS: | 0 | 8 | 27 | 13 | |||
| LIABILITIES AND EQUITY | |||||||
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts payable and accrued liabilities | 1 | 1 | 3 | 2 | |||
| Accounts payable | 1 | 1 | 3 | 2 | |||
| Debt | 0 | 0 | |||||
| Due to related parties | 0 | 0 | |||||
| Deferred revenue and credits | 0 | 0 | 0 | 0 | |||
| Other undisclosed current liabilities | 3 | 1 | 1 | 2 | |||
| Total current liabilities: | 4 | 2 | 4 | 3 | |||
| Noncurrent Liabilities | |||||||
| Long-term debt and lease obligation | 0 | 0 | |||||
| Capital lease obligations | 0 | 0 | |||||
| Liabilities, other than long-term debt | 5 | 7 | 36 | 21 | |||
| Derivative instruments and hedges, liabilities | 5 | 7 | 36 | 21 | |||
| Other undisclosed noncurrent liabilities | 0 | ||||||
| Total noncurrent liabilities: | 5 | 7 | 36 | 22 | |||
| Total liabilities: | 9 | 9 | 40 | 25 | |||
| Stockholders' equity | |||||||
| Stockholders' equity attributable to parent, including: | (9) | (1) | (13) | (12) | |||
| Common stock | 0 | 0 | 0 | 0 | |||
| Additional paid in capital | 85 | 81 | 77 | 38 | |||
| Accumulated deficit | (93) | ||||||
| Warrants and rights outstanding | 12 | ||||||
| Other undisclosed stockholders' equity attributable to parent | (82) | (90) | (62) | ||||
| Total stockholders' equity: | (9) | (1) | (13) | (12) | |||
| TOTAL LIABILITIES AND EQUITY: | 0 | 8 | 27 | 13 | |||
Income statement (P&L) ($ in millions)
| 9/30/2016 TTM | 12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|---|---|---|
| Operating expenses | (13) | (21) | (17) | (11) | ||
| Operating loss: | (13) | (21) | (17) | (11) | ||
| Nonoperating income (expense) | 2 | 29 | (23) | (4) | ||
| Debt instrument, convertible, beneficial conversion feature | 8 | |||||
| Other nonoperating income (expense) | 2 | 29 | (4) | 3 | ||
| Interest and debt expense | (0) | (0) | (2) | (6) | ||
| Net income (loss): | (12) | 8 | (42) | (21) | ||
| Other undisclosed net income attributable to parent | 0 | 0 | 2 | 6 | ||
| Net income (loss) available to common stockholders, basic: | (12) | 8 | (40) | (14) | ||
| Dilutive securities, effect on basic earnings per share | 40 | |||||
| Net income (loss) available to common stockholders, diluted: | (12) | 8 | 0 | (14) | ||
Comprehensive Income ($ in millions)
| 9/30/2016 TTM | 12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|---|---|---|
| Net income (loss): | (12) | 8 | (42) | (21) | ||
| Comprehensive income (loss), net of tax, attributable to parent: | (12) | 8 | (42) | (21) | ||
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.